ADMA Biologics Inc (NASDAQ:ADMA) was upgraded by stock analysts at Raymond James Financial, Inc. from a “market perform” rating to an “outperform” rating in a research note issued on Tuesday. The firm currently has a $5.00 target price on the biotechnology company’s stock. Raymond James Financial, Inc.’s price target would indicate a potential upside of 101.61% from the company’s previous close.
Separately, ValuEngine downgraded ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
Shares of ADMA Biologics (ADMA) opened at $2.48 on Tuesday. The company has a debt-to-equity ratio of 2.26, a quick ratio of 1.35 and a current ratio of 2.36. ADMA Biologics has a 52 week low of $2.01 and a 52 week high of $6.88.
ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Friday, August 11th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.29). The business had revenue of $3.40 million for the quarter, compared to analyst estimates of $3.52 million. ADMA Biologics had a negative net margin of 35.00% and a negative return on equity of 76.26%. equities research analysts anticipate that ADMA Biologics will post -2.25 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “ADMA Biologics Inc (ADMA) Stock Rating Upgraded by Raymond James Financial, Inc.” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://transcriptdaily.com/2017/11/14/adma-biologics-inc-adma-stock-rating-upgraded-by-raymond-james-financial-inc.html.
In other news, Director Eric I. Richman purchased 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was acquired at an average cost of $2.15 per share, for a total transaction of $53,750.00. Following the completion of the purchase, the director now owns 31,300 shares of the company’s stock, valued at $67,295. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Adam S. Grossman purchased 485,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The stock was purchased at an average price of $2.15 per share, with a total value of $1,042,750.00. The disclosure for this purchase can be found here. Insiders purchased 526,500 shares of company stock valued at $1,131,975 over the last quarter. Insiders own 60.44% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.